Progress in India in Medical Research New Treatments for Neglected Diseases from Research to Implementation

[New Delhi, India – December 3, 2010]
Over 150 Indian and international health researchers, policy makers, experts from 22 countries met on December 3rd, at the Constitutional Club in New Delhi for the 3rd International Partners meeting organized by Drugs for Neglected Diseases initiative (DNDi) in collaboration with Indian Council for Medical Research (ICMR) to stimulate greater regional research partnership to fight the most neglected diseases such as Kala-azar sleeping sickness, malaria and Chagas disease.

Dutch Government gives 14 million Euros to DNDi to fight neglected tropical diseases

[Geneva, Switzerland – December 3, 2010]
The Ministry of Foreign Affairs of the Netherlands has granted 14 million Euros to the Drugs for Neglected Diseases initiative (DNDi) to fight neglected tropical diseases. The grant will be disbursed over four years (2011-2014) and will provide critical funding for DNDi on the core disease programmes for human African trypanosomiasis, Chagas disease, and leishmaniasis. This is the second time that the Dutch government has awarded funding to DNDi.
[Nederlands]

New Potential TB Drugs to be Investigated Against Multiple Neglected Diseases

[New York, United States and Geneva, Switzerland – July 7, 2010]
A Unique Collaboration: TB Alliance and DNDi Enter Cross-Disease License Agreement to Speed Development of Novel Therapies
The Global Alliance for TB Drug Development (TB Alliance) and Drugs for Neglected Diseases initiative (DNDi) announced today a unique first-ever royalty-free license agreement between two not-for-profit drug developers that speeds progress toward markedly improved therapy of multiple neglected diseases. The TB Alliance has granted rights to DNDi to develop a class of potential anti-TB compounds that also show significant promise for treating other neglected diseases that largely affect the world’s poor. This agreement highlights the efficiency and synergy of product development partnerships (PDPs), and how investment in PDPs is producing a robust and diverse pipeline of tools to treat a wide variety of neglected diseases.

World Health Assembly: MSF and DNDi call on World Health Organization Member States to include access to diagnosis and treatment in the resolution on Chagas disease

[Geneva, Switzerland – May 17, 2010]
The Resolution ‘Chagas Disease: Control and Elimination’ to be adopted by the WHO is a step in the right direction but lacks essential elements
At the ‘World Health Assembly’ (May 17-22, 2010) in Geneva, the resolution ‘Chagas Disease: Control and Elimination’ is about to be adopted by the World Health Organization (WHO). Although this is a step in the right direction, the resolution lacks essential elements. Médecins Sans Frontières/Doctors Without Borders (MSF) and Drugs for Neglected Disease initiative (DNDi) call on WHO Member States to include in the resolution the integration of treatment and diagnosis at the primary healthcare level and increased efforts in research and development.

New agreement signed to join forces to tackle Chagas disease

[Geneva, Switzerland/Barcelona, Spain – March 15, 2010]
Today, Drugs for Neglected Diseases initiative, the Barcelona Centre for International Health Research and the Clinic Foundation for Biomedical Research signed an agreement to join forces on clinical research on Chagas disease. Dr.  Bernard Pècoul, Executive Director of the Drugs for Neglected Diseases initiative (DNDi), Dr. Pedro L. Alonso, Director of the Barcelona Centre International Health Research (CRESIB)/Hospital Clínic-Barcelona University, and Mr. Emili Bargalló, Director of the Clinic Foundation for Biomedical Research (FCRB), signed the agreement, which will allow enhancing and maximizing resources and efforts in clinical research for Chagas diseases, with the ultimate goal to improve and obtain effective treatments.
[Español]

More Sustainable Resources Needed

[February 2010]
Despite the establishment of Product Development Partnerships like DNDi and new commitments from public and private donors, funding for scientific and medical innovation for diseases that disproportionately affect the developing world remains inadequate. DNDi and the George Institute launched in February 2010 a new report on the challenges of registering new drugs for neglected diseases in the African context.

Pfizer and DNDi Advancing International Research Efforts in The Fight Against Neglected Tropical Diseases

[New York, USA, Geneva, Switzerland – November 18, 2009]
Pfizer Inc and Drugs for Neglected Diseases initiative (DNDi) have signed an agreement that is designed to facilitate advancements in the battle against human African trypanosomiasis (HAT), visceral leishmaniasis (VL) and Chagas disease, which afflict vulnerable populations in the developing world. Under the agreement, DNDi will have access to the Pfizer library of novel chemical entities, in order to screen it for compounds that have the potential to be developed into new treatments.

Chagas Disease: Break the Silence – Time to Treat

[October 1, 2009]
Santa Monica, California, USA
The Drugs for Neglected Diseases initiative (DNDi) and Doctors Without Borders/Médecins Sans Frontières (MSF) hosted a panel discussion moderated by Univision’s Julio Cesar Ortiz on Chagas disease, a largely ignored infectious disease that kills thousands every year in Latin America. Since its discovery 100 years ago, very little has been done for the millions of people infected with Chagas, including an estimated 300,000 in the US.

Eisai and DNDi Enter into a Collaboration and License Agreement To Develop a New Drug for Chagas Disease

[Geneva, Switzerland – September 29, 2009]
Eisai Co., Ltd. (“Eisai”) and the Drugs for Neglected Diseases initiative (DNDi), a non-profit independent foundation, announced today that they have signed a collaboration and license agreement for the clinical development of a promising new drug for the treatment of Chagas disease, a fatal infectious disease that threatens 100 million people in Latin America and the Caribbean.
[Español] [Português]